Belumosudil Chemical Properties

Melting point:

>228oC (dec.)

Boiling point:

682.6±55.0 °C(Predicted)

Density 

1.318±0.06 g/cm3(Predicted)

storage temp. 

2-8°C(protect from light)

solubility 

Soluble in DMSO (25 mg/ml)

pka

13?+-.0.40(Predicted)

form 

solid

color 

White

Stability:

Stable for 1 year as supplied from date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

InChIKey

GKHIVNAUVKXIIY-UHFFFAOYSA-N

SMILES

C(NC(C)C)(=O)COC1=CC=CC(C2=NC(NC3C=CC4=C(C=3)C=NN4)=C3C(=N2)C=CC=C3)=C1

Belumosudil Usage And Synthesis

Description

KD 025 is an inhibitor of Rho-associated kinase 2 (ROCK2; IC₅₀ = 0.105 μM). It is selective for ROCK2 over ROCK1 (IC₅₀ = 24 μM). KD 025 (10 μM) decreases the expression of connective tissue growth factor (CTGF) and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells. It inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 1.25 to 10 μM. KD 025 (100 and 200 mg/kg) reduces infarct volume in a mouse model of cerebral ischemia induced by transient middle cerebral artery occlusion (MCAO). It decreases disease severity in a mouse model of sclerodermatous chronic graft versus host disease (GVHD) when administered at a dose of 150 mg/kg. Formulations containing KD 025 have been used in the treatment of chronic GVHD.

Uses

KD 025 is an inhibitor of Rho-associated protein kinase II (ROCK-II), a serine/threonine kinase that regulates the formation of actin stress fibers and focal adhesions, smooth muscle contraction, and gene expression (1, 2). KD025 has been shown to reduce infarct volume after transient middle cerebral artery occlusion (2).

Indications

Belumosudil is an orally active drug approved for the treatment of chronic graft-versus-host disease (cGVHD). cGVHD is a chronic inflammatory disease that occurs in patients who have undergone allogeneic haematopoietic cell transplantation (allo-HCT), resulting in long-term multi-organ complications.

brand name

Rezurock

General Description

Class: serine-threonine kinase; Treatment: chronic GVHD; Other name: SLx-2119, KD025; Oral bioavailability = 64%; Elimination half-life = 19 h; Protein binding = 99.9%

Mechanism of action

Belumosudil is a Rho-associated coiled-coil-containing protein kinase-2 (ROCK2) inhibitor. Inhibition of ROCK2 reduces cytokine production through down-regulation of signal transduction and activation of phosphorylation of transcription factor 3 (STAT3). In addition, Belumosudil promotes the production of regulatory T cells by upregulating the phosphorylation of STAT5. These effects contribute to the reduction of symptoms in patients with cGVHD.

Synthesis

Belumosudil was synthesised as follows: bromoacetyl bromide (17.1) was reacted with isopropylamine (17.2) to form amide 17.3. Subsequent bromine substitution using methyl 3-hydroxybenzoate (17.4) formed ether 17.5. Saponification of the ester yielded carboxylic acid 17.6, which was converted to a chloroform using oxalyl chloride, and was subsequently reacted with 2-amino benzamide ( 17.7) to form amide 17.8. the ring was buckled under strong alkaline conditions to form quinazolinone 17.9, which was then chlorinated to 4-chloroquinazoline 17.10 using sulfoxide chloride. the final reaction was a direct SNAr reaction using 5-aminoindolazole (17.11), which completed the synthesis of belumosidul. the synthesis of belumosudil was completed using oxalyl chloride to convert the carboxylic acid 17.6 to a chloride. The final step of converting belumosudil to methanesulfonate is not described in the patent, but may have been achieved by treatment with methanesulfonic acid 17.

target

Primary target: ROCK2

References

[1] MARJAN BOERMA. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.[J]. Blood Coagulation & Fibrinolysis, 2008, 19 7: 709-718. DOI:10.1097/mbc.0b013e32830b2891
[2] ALEXANDRA ZANIN-ZHOROV. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111 47: 16814-16819. DOI:10.1073/pnas.1414189111
[3] R. FLYNN. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.[J]. Blood, 2016, 127 17 1: 2144-2154. DOI:10.1182/blood-2015-10-678706
[4] MADAN JAGASIA. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.[J]. Journal of Clinical Oncology, 2021, 39 17: 1888-1898. DOI:10.1200/jco.20.02754
[5] DUY TRONG VIEN DIEP. Anti-adipogenic effects of KD025 (SLx-2119), a ROCK2-specific inhibitor, in 3T3-L1 cells.[J]. Scientific Reports, 2018: 2477. DOI:10.1038/s41598-018-20821-3
[6] DUY TRONG VIEN DIEP. KD025 (SLx-2119) suppresses adipogenesis at intermediate stage in human adipose-derived stem cells.[J]. Adipocyte, 2019: 114-124. DOI:10.1080/21623945.2019.1590929
[7] LEI WEI. ROCK2 inhibition enhances the thermogenic program in white and brown fat tissue in mice[J]. FASEB Journal, 2019, 34 1: 474-493. DOI:10.1096/fj.201901174rr
[8] NHU NGUYEN QUYNH TRAN K H C. ROCK2-Specific Inhibitor KD025 Suppresses Adipocyte Differentiation by Inhibiting Casein Kinase 2.[J]. Molecules, 2021, 26 16. DOI:10.3390/molecules26164747

Belumosudil(911417-87-3)Related Product Information

• Volasertib (BI 6727)
• Dequalinium chloride
• BI 2536
• Ibrutinib
• FLUSULFAMIDE